Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

Impact · against what's priced in

Evaxion provides positive preclinical data for its EVX-V1 CMV vaccine, specifically showing that AI-discovered T-cell epitopes improve control of infection and reactivation in mice. While the lack of existing CMV vaccines confirms a high-ceiling market, the news is early-stage preclinical data, offering a modest positive catalyst for a clinical-stage company.

EVAX+0.30

No priced-in read yet